Clinical Trial

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.
Trial Details
NCT Number NCT07400003
Lead Sponsor Sinovac Biotech Co., Ltd
Conditions Herpes Zoster, mRNA Vaccine
Enrollment 519 participants
Start Date 2026-01-06
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-10